UTMD Q2 2026: Revenue Down 14%, Litigation Costs Rise, Guidance Cut
UTMD sits 34% above its 52-week low of $53.66 on light trading volume (0.2× avg).
Summary
UTMD's Q2 2026 results confirm a 14% revenue decline and reduced guidance, with rising litigation costs adding pressure. The company remains financially solid with no debt and significant cash reserves.
Key Events · Earnings and Guidance · UTMD
-
Q2 Revenue Declines 14.3%
Net sales fell to $8.53 million from $9.95 million in Q2 2025, primarily due to the loss of two major customers (PendoTECH and a China distributor) which accounted for $1.07 million of the decline.
-
Full-Year Guidance Cut
Management now projects a 10-13% sales decline for 2026, down from prior expectations of flat revenue, as new biopharma OEM sales have been slower than anticipated.
-
Litigation Expenses Escalate
Q2 2026 litigation costs were $213 higher than Q2 2025, and management now expects 2026 litigation expenses to be under $1.6 million, exceeding the prior estimate of being lower than 2025's $1.355 million.
-
Tariffs Impact Gross Margin
Filshie device tariffs totaled $156 in 1H 2026, reducing gross profit margin by 0.9 percentage points. Management expects no additional Filshie tariffs in 2H 2026.
Analysis · UTMD · Industrial Applications And Services
Utah Medical Products reported Q2 2026 revenue of $8.53 million, down 14.3% year-over-year, driven by the loss of its two largest customers. Net income fell 11.9% to $2.69 million, and full-year guidance was slashed to a 10-13% sales decline. The company faces higher litigation expenses, with 2026 costs now expected to be under $1.6 million, up from prior estimates. Despite the challenges, UTMD maintains a strong balance sheet with $87.5 million in cash and no debt, and continues to repurchase shares.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.4% of the 1987 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UTMD was trading at $72.13 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $229.7M. The 52-week trading range was $53.66 to $75.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.